Abstract 326P
Background
Indocyanine green (ICG) has the potential to improve sentinel lymph node (SLN) mapping. This current cohort study was designed to assess the value of ICG using a new ICG handheld system with radioisotope (RI) in patients with early breast cancer undergoing SLN biopsy.
Methods
A prospective self-controlled trial compared the detection efficacies of ICG and RI was conducted. Concordance (ICG and RI-positive cases divided by RI-positive cases) and reverse concordance (ICG and RI-positive cases divided by ICG-positive cases) were documented and adverse event were also assessed.
Results
Of 69 patients (median age 56.7 (range 33-85), median BMI 22.6 (range 17.0 – 44.5)) enrolled between 2019 and 2021, 71 SLN biopsies were performed. Sixty-one (85.9%) underwent upfront surgery, while ten (14.1%) were given neoadjuvant treatment. Thirty-four breast-conserving surgeries (BCS) (47.9%), 33 mastectomies (46.5%) and four cryotherapies (5.6%) were performed. No adverse event nor skin staining were reported. The SLN identification rate was 87.3% (62/71) for ICG and 95.8% (68/71) for RI (p=0.13). Dual tracer method resulted in 97.2% successful identification, significantly superior to ICG alone (p=0.04, OR 5.0, CI 1.0-24.1) and and was in line with the reported rate of 96.7% (94.3-99.1)1 by blue dye and RI. Concordance and reverse concordance rates were 89.7% and 98.4%, respectively. A median of 2 lymph nodes was detected by both ICG (range 0 – 6) and IR (range 0 – 5) with no statistical difference (p=0.60). Of 10 cases with 13 metastatic nodes confirmed by histology, both ICG and RI achieved 100% concordance rates. Breast conserving treatments had a higher ICG failure rate compared to mastectomy (21.1% vs 3.0%, p=0.05, OR 8.5, CI 1.0-72.4). In addition, among three cases with prior surgery, two failed ICG SLN identification. Meanwhile, age, BMI, tumour location, multifocality, neoadjuvant treatment, and ICG volume showed no significant correlation with ICG detection rate.
Conclusions
The combined use of ICG and RI ensures adequate SLN identification without problems known with the use of blue dye, such as skin staining and anaphylaxis. A higher failure rate was noted in patients with breast-conserving treatments for ICG tracing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
272P - Primary prevention of bone fractures in patients (pts) with hormone receptor (HR)+ early breast cancer (EBC) during adjuvant hormonal therapy (HT): The predict & prevent project (P&P)
Presenter: Stefania Gori
Session: Poster session 02
273P - A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2
Presenter: Patrick Neven
Session: Poster session 02
274P - Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study
Presenter: Joyce O'Shaughnessy
Session: Poster session 02
275P - Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)
Presenter: Francesco Schettini
Session: Poster session 02
276P - Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT)
Presenter: Luca Mastrantoni
Session: Poster session 02
277P - Fat body mass independently predicts incident vertebral fractures in breast cancer patients given adjuvant aromatase inhibitor therapy and denosumab
Presenter: Greta Schivardi
Session: Poster session 02
278P - Association between tamoxifen and endoxifen plasma levels and clotting proteins in patients with primary breast cancer
Presenter: Daan van Dorst
Session: Poster session 02
279P - Early changes in bone turnover biomarkers during AI therapy are related to loss bone mineral density, data of the B-ABLE cohort
Presenter: Tamara Martos Cardenas
Session: Poster session 02
280P - Adjuvant aromatase inhibitors in patients with PIK3CA mutation early breast cancer
Presenter: Kristin Reinhardt
Session: Poster session 02